358 related articles for article (PubMed ID: 33890833)
1. Novel therapeutic approaches for cutaneous T cell lymphomas.
Pavlidis A; Piperi C; Papadavid E
Expert Rev Clin Immunol; 2021 Jun; 17(6):629-641. PubMed ID: 33890833
[No Abstract] [Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
3. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
4. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
6. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
7. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
Luna DE; Shinohara MM
Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
9. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Trager MH; Geskin LJ
G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
11. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
12. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Photiou L; van der Weyden C; McCormack C; Miles Prince H
Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
[TBL] [Abstract][Full Text] [Related]
13. How I treat mycosis fungoides and Sézary syndrome.
Prince HM; Whittaker S; Hoppe RT
Blood; 2009 Nov; 114(20):4337-53. PubMed ID: 19696197
[TBL] [Abstract][Full Text] [Related]
14. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
15. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
Atilla PA; Atilla E
Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
[TBL] [Abstract][Full Text] [Related]
16. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
[TBL] [Abstract][Full Text] [Related]
18. How I treat mycosis fungoides and Sézary syndrome.
Whittaker S; Hoppe R; Prince HM
Blood; 2016 Jun; 127(25):3142-53. PubMed ID: 27151889
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma.
Goyal A; Foss F
Expert Rev Anticancer Ther; 2024; 24(1-2):41-58. PubMed ID: 38224371
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments.
Sivanand A; Surmanowicz P; Alhusayen R; Hull P; Litvinov IV; Zhou Y; Gniadecki R
J Cutan Med Surg; 2019; 23(5):537-544. PubMed ID: 31353944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]